^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT327

    i
    Other names: BNT327, PM8002, PM 8002
    Company:
    BioNTech, Biotheus
    Drug class:
    PD-L1 inhibitor, VEGF-A inhibitor
    Related drugs:
    4ms
    A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC (clinicaltrials.gov)
    P2/3, N=445, Recruiting, Biotheus Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Tecentriq (atezolizumab) • etoposide IV • BNT327
    10ms
    A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC (clinicaltrials.gov)
    P2/3, N=374, Recruiting, Biotheus Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 expression • EGFR mutation
    |
    carboplatin • pemetrexed • BNT327
    10ms
    A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM (clinicaltrials.gov)
    P2, N=55, Recruiting, Biotheus Inc.
    New P2 trial • Combination therapy
    |
    cisplatin • carboplatin • pemetrexed • BNT327
    10ms
    A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Biotheus Inc.
    New P1/2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    albumin-bound paclitaxel • BNT327
    10ms
    PM8002 in the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=380, Recruiting, Biotheus Inc.
    New P1/2 trial • Metastases
    |
    BNT327
    11ms
    A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC (clinicaltrials.gov)
    P2, N=99, Recruiting, Biotheus Inc.
    New P2 trial • Combination therapy
    |
    paclitaxel • BNT327
    11ms
    A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN (clinicaltrials.gov)
    P2, N=60, Recruiting, Biotheus Inc.
    New P2 trial • Combination therapy
    |
    5-fluorouracil • irinotecan • leucovorin calcium • BNT327
    12ms
    PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=35, Recruiting, Biotheus Inc.
    New P2 trial • Combination therapy
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • BNT327
    12ms
    A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC (clinicaltrials.gov)
    P2/3, N=445, Not yet recruiting, Biotheus Inc.
    New P2/3 trial • Combination therapy
    |
    Tecentriq (atezolizumab) • etoposide IV • BNT327